Rex Mowat, MD
Hematology & Oncology · Toledo, OHNPI 1346247251
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Daiichi Sankyo Inc. at 58.3% of the total. Reporting peaked in 2020 at $49,485 and has fallen 93.4% since, to $3,287 in 2025. Among hematology & oncology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 278 payments — averaging $425.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$69K
- Cornerstone Specialty Network LLC$43K
- Geron Corporation$960
- Incyte Corporation$775
- AstraZeneca$551
- Johnson & Johnson$309
- plus $4K from 41 others
Across 454 payments — averaging $2415.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$309K
- AbbVie$157K
- Astrazeneca UK Limited$78K
- Genentech, Inc.$69K
- Pfizer$53K
- Eli Lilly$46K
- plus $385K from 24 others
What the payments were for
- Consulting fees$66,42456%
- Speaking & faculty fees$39,02433%
- Travel & lodging$5,2974%
- Food & beverage$7,3436%
- Education$2840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$67,663
- RYTELO$960
- DATROWAY$833
- JAKAFI$645
- FOUNDATIONACT$300
- FOUNDATIONFOCUS$300
- FOUNDATIONONE CDX$300
- FOUNDATIONONE HEME$300
- FOUNDATIONONE$300
- WAYRILZ$141
- TAGRISSO$131
- TUKYSA$121
- EPKINLY$118
- XT CDX$101
How this compares
$118,372 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 63 | $967,006 |
| ImbruvicaIbrutinib | 45 | $682,678 |
| EmpaveliPegcetacoplan | 11 | $520,572 |
| BrukinsaZanubrutinib | 23 | $250,513 |
| CalquenceAcalabrutinib Maleate | 15 | $227,765 |
| SprycelDasatinib | 11 | $201,053 |
| XtandiEnzalutamide | 12 | $179,975 |
| AlecensaAlectinib Hcl | 11 | $178,622 |
| PromactaEltrombopag Olamine | 25 | $178,311 |
| Abiraterone Acetate | 19 | $36,879 |
| XareltoRivaroxaban | 44 | $35,759 |
| CotellicCobimetinib Fumarate | 11 | $27,104 |
| Anastrozole | 161 | $4,623 |
| Exemestane | 15 | $2,807 |
| Letrozole | 77 | $2,241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance | $58 | $967,00663 claims |
| Apellis Pharmaceuticals, Inc.Empaveli | $17 | $520,57211 claims |
| AstraZenecaCalquence | $551 | $227,76515 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $164 | $201,05311 claims |
| Astellas Pharma US IncXtandi | $131 | $179,97512 claims |
| Genentech USA, Inc.Alecensa | $64 | $178,62211 claims |
| NovartisPromacta | $285 | $178,31125 claims |
| Johnson & JohnsonXarelto | $309 | $35,75944 claims |
| Lilly USA, LLCOlanzapine | $60 | $2612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Toledo
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Alejandro CalvoKettering$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.